Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer
Status:
Recruiting
Trial end date:
2024-09-30
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of brigatinib and binimetinib in
treating patients with stage IIIB-IV non-small cell lung cancer and a type of gene mutation
called a rearrangement in the ALK or ROS1 genes. Brigatinib and binimetinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.